Docoh
Loading...

GRTS Gritstone Bio

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Wednesday
19 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's morning trading, 400 companies set new 52-week lows.
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
13 Jan 22
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
21 Stocks Moving in Wednesday's Pre-Market Session
5 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Wejo Group Ltd (NASDAQ: WEJO) rose 37% to $8.63 in pre-market trading after the company announced a new connected vehicle platform with Microsoft, called Wejo Neural Edge.
45 Biggest Movers From Yesterday
5 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55.
Mid-Afternoon Market Update: Dow Jumps 250 Points; Avrobio Shares Slide
4 Jan 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Tuesday, the Dow traded up 0.70% to 36,839.62 while the NASDAQ fell 1.57% to 15,583.77. The S&P also fell, dropping 0.03% to 4,794.93.
12 Health Care Stocks Moving In Tuesday's Intraday Session
4 Jan 22
Movers
Mid-Day Market Update: Nasdaq Dips 250 Points; TherapeuticsMD Shares Surge
4 Jan 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Tuesday, the Dow traded up 0.66% to 36,827.65 while the NASDAQ fell 1.63% to 15,574.50. The S&P also fell, dropping 0.08% to 4,792.93.
34 Stocks Moving In Tuesday's Mid-Day Session
4 Jan 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Drops To 58.7
4 Jan 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Tuesday, the Dow traded up 0.74% to 36,857.55 while the NASDAQ fell 0.14% to 15,811.30. The S&P also rose, gaining 0.40% to 4,815.75.
Gritstone Bio's COVID-19 Booster Dose Shows Early Neutralizing Antibody Responses
4 Jan 22
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
Gritstone bio Inc (NASDAQ: GRTS) has
Gritstone Announces Clinical Results From First Cohort Of Phase 1 Study Evaluating T Cell-Enhanced samRNA Vaccine Against COVID-19
4 Jan 22
Biotech, News, FDA, General
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19 -- Single 10 µg dose of samRNA
Gritstone bio, CEPI Expand COVID-19 Vaccine Agreement to Combat Omicron Variant
6 Dec 21
Biotech, News, Health Care, Financing, Small Cap, General
Gritstone bio Inc (NASDAQ: GRTS) and Coalition for Epidemic Preparedness Innovations (CEPI) have
Gritstone bio And CEPI Expand Vaccine Agreement In Order To Support The Development Of A Self-amplifying mRNA Vaccine Designed To Tackle The Omicron COVID-19 Variant
6 Dec 21
News, Contracts
Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, today
52 Biggest Movers From Yesterday
1 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's After-Market Session
30 Nov 21
Movers
Gainers Lannett (NYSE:LCI) shares rose 11.61% to $1.73 during Tuesday's after-market session. The market value of their outstanding shares is at $74.3 million.
12 Health Care Stocks Moving In Monday's After-Market Session
29 Nov 21
Movers
Gainers
Gritstone Says Omicron Mutations Minimally Impact T-Cell Epitope Sequences In Its COVID-19 Vaccines
29 Nov 21
Biotech, News, Health Care, Small Cap, General
Gritstone bio Inc (NASDAQ: GRTS) announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are
The Omicron Variant Of SARS-CoV-2 Has Minimal Impact On The T Cell Epitopes Contained Within Gritstone's Self-Amplifying mRNA COVID-19 Vaccines
29 Nov 21
News
Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the SARS-CoV-2 T cell epitopes (TCEs) administered
Gritstone Announces Preclinical Data In Non-Human Primate Challenge Study With Second-Generation COVID-19 Vaccine Against SARS-CoV-2
10 Nov 21
Biotech, News, General
Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques Potential for equivalent or more potent immune
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
4 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK

Press releases

From Benzinga Pro
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 Jan 22
Press Releases, General
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA) reduction with
Gritstone Announces Presentations during Three Upcoming Investor Conferences
30 Dec 21
News, Press Releases
EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today
Gritstone Announces Changes to Its Board of Directors
17 Dec 21
Press Releases
-- Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1, 2022 -- --
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Dec 21
Press Releases
EMERYVILLE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today
Direxion Launches mRNA ETF (MSGR)
9 Dec 21
Press Releases
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of
The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone's Self-Amplifying mRNA COVID-19 Vaccines
29 Nov 21
Health Care, Press Releases
Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstone's COVID-19 vaccines (CORAL program) T cell immunity against conserved
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 Nov 21
Markets, Press Releases
EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
10 Nov 21
Health Care, Press Releases, General
Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques Potential for equivalent or more potent immune